company background image
STAB

Statera Biopharma NasdaqCM:STAB Stock Report

Last Price

US$0.13

Market Cap

US$6.5m

7D

-13.6%

1Y

-94.3%

Updated

01 Oct, 2022

Data

Company Financials
STAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

STAB Stock Overview

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.

Statera Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Statera Biopharma
Historical stock prices
Current Share PriceUS$0.13
52 Week HighUS$4.18
52 Week LowUS$0.11
Beta0
1 Month Change-28.13%
3 Month Change-52.89%
1 Year Change-94.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-97.41%

Recent News & Updates

Sep 12

Statera Biopharma updates on Nasdaq Listing Status

Statera Biopharma (NASDAQ:STAB) provided an update on its request for a hearing before the Nasdaq Hearings Panel caused by delayed filing of its form 10-Q for the June quarter with the U.S. SEC in a timely manner. STAB had previously said that it had got non-compliance notices from Nasdaq regarding its inability to file its form 10-K for fiscal year 2021 and form 10-Q for the March quarter. The company timely requested a hearing and will request a further stay of any delisting action by Nasdaq pending the hearing, which is scheduled for October 6, 2022, and expiration of any extension that may be granted by the Panel. Last month, Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq. Shares are up 6.44% after-hours.

Aug 25

Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq

Statera Biopharma (NASDAQ:STAB) on Thursday said it had got an expected additional notice of non-compliance from Nasdaq due to the company's failure to file its form 10-Q for the June quarter with the U.S. SEC in a timely manner. STAB had previously said that it had got non-compliance notices from Nasdaq regarding its inability to file its form 10-K for fiscal year 2021 and form 10-Q for the March quarter. Statera (STAB) said it plans to provide the exchange with an update regarding its compliance efforts. The company also said it plans to submit a timely plan to regain compliance. STAB stock was unchanged at $0.22 after hours.

Shareholder Returns

STABUS BiotechsUS Market
7D-13.6%0.4%-2.5%
1Y-94.3%-25.6%-23.2%

Return vs Industry: STAB underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: STAB underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is STAB's price volatile compared to industry and market?
STAB volatility
STAB Average Weekly Movement10.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: STAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: STAB's weekly volatility has decreased from 19% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a19Mike Handleyhttps://www.staterabiopharma.com

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis.

Statera Biopharma Fundamentals Summary

How do Statera Biopharma's earnings and revenue compare to its market cap?
STAB fundamental statistics
Market CapUS$6.49m
Earnings (TTM)-US$28.84m
Revenue (TTM)US$236.52k

27.5x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STAB income statement (TTM)
RevenueUS$236.52k
Cost of RevenueUS$115.93k
Gross ProfitUS$120.59k
Other ExpensesUS$28.96m
Earnings-US$28.84m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin50.99%
Net Profit Margin-12,194.20%
Debt/Equity Ratio21.6%

How did STAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is STAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STAB?

Other financial metrics that can be useful for relative valuation.

STAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue59.4x
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does STAB's PS Ratio compare to its peers?

STAB PS Ratio vs Peers
The above table shows the PS ratio for STAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8x
NPHC Nutra Pharma
40xn/aUS$6.1m
ANPC AnPac Bio-Medical Science
2.4xn/aUS$6.0m
SONN Sonnet BioTherapeutics Holdings
9.3x-122.9%US$7.2m
ACOR Acorda Therapeutics
0.06xn/aUS$7.3m
STAB Statera Biopharma
27.5xn/aUS$6.5m

Price-To-Sales vs Peers: STAB is expensive based on its Price-To-Sales Ratio (27.5x) compared to the peer average (8x).


Price to Earnings Ratio vs Industry

How does STAB's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: STAB is expensive based on its Price-To-Sales Ratio (27.5x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is STAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate STAB's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of STAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate STAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STAB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Statera Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Statera Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of STAB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Statera Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-185.7%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: STAB is currently unprofitable.

Growing Profit Margin: STAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if STAB's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare STAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: STAB has a negative Return on Equity (-38.89%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Statera Biopharma's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: STAB's short term assets ($13.3M) exceed its short term liabilities ($10.2M).

Long Term Liabilities: STAB's short term assets ($13.3M) do not cover its long term liabilities ($13.7M).


Debt to Equity History and Analysis

Debt Level: STAB's net debt to equity ratio (8.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if STAB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if STAB has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if STAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Statera Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Statera Biopharma Dividend Yield vs Market
How does Statera Biopharma dividend yield compare to the market?
SegmentDividend Yield
Company (Statera Biopharma)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Statera Biopharma)n/a

Notable Dividend: Unable to evaluate STAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as STAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Mike Handley (50 yo)

1.17yrs

Tenure

US$2,697,600

Compensation

Mr. Michael Kevin Handley, also known as Mike, serves as President, Chief Executive Officer, Director and Chairman of the Board at Sparta Healthcare Acquisition Corp. (upon closing of the merger with old C...


CEO Compensation Analysis

Mike Handley's Compensation vs Statera Biopharma Earnings
How has Mike Handley's remuneration changed compared to Statera Biopharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$3mUS$281k

-US$12m

Compensation vs Market: Insufficient data to establish whether Mike's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.


Leadership Team

Experienced Management: STAB's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: STAB's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of STAB?
Owner TypeNumber of SharesOwnership Percentage
Private Companies557,4721.1%
Institutions3,205,6026.4%
Public Companies3,296,5846.6%
Individual Insiders12,964,86225.9%
General Public29,996,11760.0%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 95%.


Top Shareholders

Top 25 shareholders own 39.52% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.91%
David Davidovich
6,459,948$838.5k0%no data
6.59%
Immune Therapeutics, Inc.
3,296,584$427.9k0%no data
4.73%
Robert Dailey
2,363,848$306.8k0%no data
3.27%
Renaissance Technologies LLC
1,636,235$212.4k851.75%no data
2.57%
Noreen Griffin
1,283,189$166.6k0%no data
2.25%
James Harpel
1,126,956$146.3k0%no data
1.21%
Robert Buckheit
607,278$78.8k0%no data
0.93%
Michael Handley
463,156$60.1k0%no data
0.78%
The Vanguard Group, Inc.
389,110$50.5k0%no data
0.6%
Acuity Partners, LLC
299,000$38.8k0%no data
0.5%
Acuity Opportunities Fund I LLC
250,000$32.5k0%no data
0.44%
Peter Aronstam
220,719$28.6k0%no data
0.34%
Northern Trust Global Investments
171,110$22.2k0%no data
0.32%
Clifford Selsky
158,599$20.6k0%no data
0.3%
Susquehanna International Group, LLP, Asset Management Arm
151,848$19.7k0%no data
0.26%
Geode Capital Management, LLC
130,774$17.0k0%no data
0.23%
BlackRock, Inc.
115,195$15.0k96.81%no data
0.22%
Raymond James Financial Services Advisors, Inc.
112,250$14.6k0%no data
0.2%
Taunia Markvicka
100,000$13.0k0%no data
0.19%
Cozette McAvoy
95,160$12.4k0%no data
0.15%
Andrei Gudkov
75,869$9.8k0%no data
0.14%
Cambridge Investment Research Advisors, Inc.
68,825$8.9k-2.02%no data
0.14%
State Street Global Advisors, Inc.
68,247$8.9k0%no data
0.12%
T. Rowe Price Group, Inc.
61,200$7.9k423.08%no data
0.12%
SunAmerica Asset Management, LLC
61,200$7.9k423.08%no data

Company Information

Statera Biopharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Statera Biopharma, Inc.
  • Ticker: STAB
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$6.493m
  • Shares outstanding: 50.02m
  • Website: https://www.staterabiopharma.com

Number of Employees


Location

  • Statera Biopharma, Inc.
  • 2537 Research Boulevard
  • Suite 201
  • Fort Collins
  • Colorado
  • 80526
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STABNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDJul 2021
7CB0DB (Deutsche Boerse AG)YesNew Common StockDEEURJul 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/01 00:00
End of Day Share Price2022/09/30 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.